Organophosphorus ester-induced delayed neurotoxicity

Annual Review of Pharmacology and Toxicology
M B Abou-Donia

Abstract

In certain animals, including humans, exposure to some organophosphorus esters causes delayed neurotoxicity (OPIDN). The clinical condition becomes manifest after a delay period, first as ataxia, followed by paralysis. Lesions are characterized by degeneration of axons with subsequent secondary degeneration of myelin in the peripheral and central nervous systems. Recovery is only likely in mild cases, whereas more severe cases show symptoms of an upper motor neuron lesion in the lower limbs. The risk of use of these chemicals is related not only to human sensitivity to this syndrome, but also to the fact that in most disasters involving OPIDN, humans were the prime victims. Therefore, the neurotoxic action of a chemical is of great significance, since pesticides with this property are not recommended for use. Although OPIDN has been recognized for over a half a century, its mechanism of action is still unknown. It is believed, however, that the initial target in OPIDN is the phosphorylation of a neurotoxicity target protein in the nervous system. Study of the relationship between the chemical structure of organophosphorus esters and their neurotoxic potencies suggests that two hydrophobic areas may be present in the vicinity of...Continue Reading

Citations

Sep 1, 1994·Neurochemical Research·C L LanningM B Abou-Donia
Nov 1, 1983·Archives of Environmental Contamination and Toxicology·B M FrancisS W Fisher
May 1, 1983·Archives of Toxicology·E Vilanova, J L Vicedo
Oct 1, 1984·Bulletin of Environmental Contamination and Toxicology·B W WilsonJ B Knaak
Jun 27, 2006·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Pardeep SidhuD K Dhawan
Aug 29, 2006·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Ajay GoelD K Dhawan
Jun 12, 2009·Cellular and Molecular Neurobiology·Anwar MasoudRajat Sandhir
Jan 1, 1989·Biochemical Pharmacology·C N Pope, S S Padilla
Jan 1, 1984·The International Journal of Biochemistry·J M Chemnitius, R Zech
Jan 1, 1990·The International Journal of Biochemistry·L Gay, M Ehrich
Apr 1, 1993·Journal of the Neurological Sciences·C M Poser
Jan 1, 1987·Pharmacology, Biochemistry, and Behavior·A C CollinsL J Medhurst
Apr 1, 1987·Pharmacology, Biochemistry, and Behavior·A SmolenA C Collins
Jan 1, 1992·Clinical Neurology and Neurosurgery·J L De BleeckerJ L Willems
May 1, 1983·Brain Research Bulletin·K C Sikora-VanmeterP A Grieve

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.